Non-Small Cell Lung Cancer:
Mastering New Therapies

Program Overview

Medical professionals who treat lung cancer need to understand how cancer signaling pathways relate to tumor heterogeneity, diagnostic markers, targeted therapies, first-line and second-line treatment decisions and assessing new therapies in development.

Three webcasts presented by leaders in lung cancer research and treatment will review recent advances and current practice on specific topics, and discuss best practice in the context of case presentations.

Module 1: Molecular Profiling
Module 2: EGFR Inhibitors
Module 3: New Targeted Therapies

Target Audience: This program is designed for physicians and other medical professionals involved in the clinical care of patients with lung cancer.

Faculty Listing:
Thomas J. Lynch, Jr., MD
Smilow Cancer Hospital at Yale
New Haven, Connecticut

Lecia V. Sequist, MD, MPH
Massachusetts General Hospital
Boston, Massachusetts

Joel W. Neal, MD, PhD
Stanford University Medical Center
Stanford, California

Pasi A. Jänne, MD, PhD
Dana Farber Cancer Institute
Boston, Massachusetts

Module 1: Molecular Profiling
Credit Hours	Credit Type
1.0	AMA PRA

 

Module 2: EGFR Inhibitors
Credit Hours	Credit Type
1.0	AMA PRA

 

Module 3: New Targeted Therapies
Credit Hours	Credit Type
1.75	AMA PRA

 

[Back to top]

[Back to Activity Home]